This paper examines the changing environment for marketed products, including an analysis of emerging markets, recent divestment discussions, challenges in the current model, and a proposed alternative view of how biopharmaceutical companies can maintain the licenses of their marketed products more cost effectively and thereby generate greater net returns.

For information on our pharmacovigilance services, please click here.